financetom
Business
financetom
/
Business
/
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
Jul 11, 2025 6:34 AM

MUNICH (Reuters) -BMW's CEO said on Friday he was optimistic that the European Union and the United States would soon reach a "manageable" agreement on auto import tariffs, potentially including a mechanism to offset imports with exports.

Oliver Zipse's comments come as Europe awaits a letter from the U.S. administration under Donald Trump that could outline the framework of a trade deal and clarify tariff levels on European automotive exports. Trump said on Thursday the EU could receive a letter on tariff rates by Friday.

"I'm optimistic that there will be a manageable outcome but we have to wait for the result," Zipse told journalists at a company event in Munich on Friday.

He said a possible "netting mechanism" could be part of the deal, allowing exports from the U.S. to offset imports. BMW stands to benefit from such an arrangement, as its largest production site is in Spartanburg, South Carolina.

The mechanism could be based on the value of exports out of the U.S. market - more than $10 billion in 2024 in BMW's case - rather than the number of exported vehicles, he said.

If both sides were to agree on such a mechanism, it could also benefit imports of auto parts, according to people familiar with the matter.

"We have an important point because we are the largest car exporter in the U.S." Zipse said, referring to the 225,000 cars it exported out of the country in 2024.

Hefty tariffs on car imports to the U.S. have left European carmakers scrambling to respond while hoping for a deal to minimise their impact in talks between Washington and the European Commission.

Sources told Reuters earlier this week that Brussels had proposed a package of measures to ease the pressure, including export and investment credits and mutual reductions in existing tariff rates.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies
Jun 26, 2025
June 26 (Reuters) - Pfizer's ( PFE ) hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday. The data comes months after the company decided to stop global development and sale of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors....
Mobix Labs Makes Unsolicited Offer to Acquire Peraso in Premium All-Stock Deal
Mobix Labs Makes Unsolicited Offer to Acquire Peraso in Premium All-Stock Deal
Jun 26, 2025
07:39 AM EDT, 06/26/2025 (MT Newswires) -- Mobix Labs ( MOBX ) said Thursday that it submitted an unsolicited, non-binding proposal to acquire Peraso (PRSO) in a stock-for-stock deal at a 20% premium over Peraso's 30-day average closing price as of June 10, 2025. The proposed merger would create a company with an estimated $20 million in annual revenue, enhancing...
Aldeyra Therapeutics Receives FDA Special Protocol Assessment Agreement for ADX-2191 Trial
Aldeyra Therapeutics Receives FDA Special Protocol Assessment Agreement for ADX-2191 Trial
Jun 26, 2025
07:39 AM EDT, 06/26/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday that it has received a Special Protocol Assessment agreement letter from the US Food and Drug Administration for a clinical trial of ADX-2191 in primary vitreoretinal lymphoma, a rare and potentially fatal cancer. The proposed clinical trial under the Special Protocol Assessment will compare cancer cell...
Copyright 2023-2026 - www.financetom.com All Rights Reserved